Filtros de búsqueda

Lista de obras de

"Cup-like" blasts and NPM1 and FLT3 (ITD) mutations in acute myeloid leukemia (AML).

artículo científico publicado en 2013

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

artículo científico publicado en 2004

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia

artículo científico publicado en 2013

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

artículo científico publicado en 2017

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2010

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome

artículo científico publicado en 2011

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

artículo científico publicado en 2008

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes

artículo científico publicado en 2002

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

artículo científico publicado en 2010

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities

artículo científico publicado en 2012

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

artículo científico publicado en 2007

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

artículo científico publicado en 2014

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)

artículo científico publicado en 2005

A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia

artículo científico publicado en 2012

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

artículo científico publicado en 2011

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2008

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

artículo científico publicado en 2003

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

artículo científico publicado en 2006

A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center

artículo científico publicado en 2014

Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia

artículo científico publicado en 2011

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

artículo científico publicado en 2012

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

artículo científico publicado en 2008

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

artículo científico publicado en 2003

Adult acute lymphoblastic leukemia: concepts and strategies

artículo científico publicado en 2010

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemot

artículo científico publicado en 2009

Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendium.

artículo científico publicado en 2014

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

artículo científico publicado en 2010

Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy

artículo científico publicado en 2004

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

artículo científico publicado en 2003

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

artículo científico publicado en 2010

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

artículo científico publicado en 2007

Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome

artículo científico publicado en 2011

At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells

artículo científico publicado en 2016

Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells

artículo científico publicado en 2006

Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia

artículo científico publicado en 2015

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

artículo científico publicado en 2013

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study

artículo científico publicado en 2007

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia

artículo científico publicado en 2008

Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

artículo científico publicado en 2011

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia

artículo científico publicado en 2002

Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia

artículo científico publicado en 2005

Cause of death in patients with lower-risk myelodysplastic syndrome

artículo científico publicado en 2010

Central nervous system relapse in adults with acute lymphoblastic leukemia

artículo científico publicado en 2002

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

artículo científico publicado en 2010

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

artículo científico publicado en 2009

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

artículo científico publicado en 2010

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

artículo científico publicado en 2005

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

artículo científico publicado en 2006

Chronic myelogenous leukemia: a review and update of therapeutic strategies

artículo científico publicado en 2003

Chronic myelogenous leukemia: update on biology and treatment

artículo científico publicado en 1999

Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature

artículo científico publicado en 2004

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

artículo científico publicado en 2009

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

artículo científico publicado en 2012

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

artículo científico publicado en 2006

Clofarabine combinations as acute myeloid leukemia salvage therapy

artículo científico publicado en 2008

Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

artículo científico publicado en 2012

Clofarabine in leukemia

artículo científico publicado en 2010

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

artículo científico publicado en 2012

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

scientific article published on 26 January 2012

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2013

Clofarabine: past, present, and future

artículo científico publicado en 2007

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

artículo científico publicado en 2015

Commentary: effect of flavonoids on normal and leukemic cells

artículo científico publicado en 2003

Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

artículo científico publicado en 2005

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

artículo científico publicado en 2008

Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease

artículo científico publicado en 2011

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration ⬇️

artículo científico publicado el 24 de agosto de 2010

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

artículo científico publicado en 2013

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

artículo científico publicado en 2002

Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes

artículo científico publicado en 2005

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

artículo científico publicado en 2009

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

artículo científico publicado en 2005

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

artículo científico publicado en 2013

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

artículo científico publicado en 2008

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

artículo científico publicado en 2003

Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.

artículo científico publicado en 2003

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2009

Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.

artículo científico publicado en 2003

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2012

Eradication of minimal residual disease in hairy cell leukemia

artículo científico publicado en 2006

Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy

artículo científico publicado en 2013

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

artículo científico publicado en 2004

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2015

Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

artículo científico publicado en 2012

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

artículo científico publicado en 2010

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia

artículo científico publicado en 2013

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia

artículo científico publicado en 2015

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

artículo científico publicado en 2011

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

artículo científico publicado en 2009

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

artículo científico publicado en 2003

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

artículo científico publicado en 2011

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

artículo científico publicado en 2014

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

artículo científico publicado en 2003

Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia

artículo científico publicado en 2003

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

artículo científico publicado en 2013

Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission.

artículo científico publicado en 2004

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

artículo científico publicado en 2003

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

artículo científico publicado en 2017

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia

artículo científico publicado en 2002

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

artículo científico publicado en 2011

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

artículo científico publicado en 2010

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

artículo científico publicado en 2002

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

artículo científico publicado en 2008

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

artículo científico publicado en 2002

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

artículo científico publicado en 2002

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

artículo científico publicado en 2003

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

artículo científico publicado en 2002

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

artículo científico publicado en 2012

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

artículo científico publicado en 2011

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

artículo científico publicado en 2011

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

artículo científico publicado en 2012

Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia

artículo científico publicado en 2014

Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience

artículo científico publicado en 2009

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

artículo científico publicado en 2003

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

artículo científico publicado en 2012

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

artículo científico publicado en 2010

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study

artículo científico publicado en 2010

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

artículo científico publicado en 2004

Is acute myeloid leukemia a liquid tumor?

artículo científico publicado en 2013

Kit inhibitor APcK110 extends survival in an AML xenograft mouse model

artículo científico publicado en 2010

Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells

artículo científico publicado en 2009

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

artículo científico publicado en 2014

Last exit clofarabine?

artículo científico publicado en 2009

Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

artículo científico publicado en 2010

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

artículo científico publicado en 2008

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

artículo científico publicado en 2016

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody

artículo científico publicado en 2012

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

artículo científico publicado en 2016

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

artículo científico publicado en 2004

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

artículo científico publicado en 2004

Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience

artículo científico publicado en 2004

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia

artículo científico publicado en 2003

Modern treatment programs for adults with acute lymphoblastic leukemia

artículo científico publicado en 2007

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

artículo científico publicado en 2005

Monitoring of minimal residual disease in chronic myeloid leukemia

artículo científico publicado en 2004

Monoclonal antibodies in chronic lymphocytic leukemia

artículo científico publicado en 2006

Monoclonal antibody combinations in CLL: evolving strategies

artículo científico publicado en 2006

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2012

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

artículo científico publicado en 2011

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

artículo científico publicado en 2013

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

artículo científico publicado en 2003

N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).

artículo científico publicado en 2003

New aspects of the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2006

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

artículo científico publicado en 2012

New nucleoside analogues in clinical development

artículo científico publicado el 1 de enero de 2002

Novel therapies for myelodysplastic syndromes

artículo científico publicado en 2004

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

artículo científico publicado en 2016

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

artículo científico publicado en 2006

Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

artículo científico publicado en 2010

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

artículo científico publicado en 2012

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

artículo científico publicado en 2008

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission

artículo científico publicado en 2010

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

artículo científico publicado en 2009

Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

artículo científico publicado en 2010

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

artículo científico publicado en 2004

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure

artículo científico publicado en 2015

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

artículo científico publicado en 2014

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

artículo científico publicado en 2014

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia

artículo científico publicado en 2011

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

artículo científico publicado en 2013

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia

artículo científico publicado en 2011

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

artículo científico publicado en 2011

Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.

artículo científico publicado en 2003

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia

artículo científico publicado en 2009

Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies

artículo científico publicado en 2008

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

artículo científico publicado en 2012

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

artículo científico publicado en 2003

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

artículo científico publicado en 2007

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

artículo científico publicado en 2006

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

artículo científico publicado en 2011

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

artículo científico publicado en 2003

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

artículo científico publicado en 2013

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

artículo científico publicado en 2011

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

artículo científico publicado en 2016

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

artículo científico publicado en 2012

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2013

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

artículo científico publicado en 2003

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

artículo científico publicado en 2009

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

artículo científico publicado en 2003

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies

artículo científico publicado en 2013

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

artículo científico publicado en 2005

Phase I study of bortezomib in refractory or relapsed acute leukemias

artículo científico publicado en 2004

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

artículo científico publicado en 2005

Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia

artículo científico publicado en 2016

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

artículo científico publicado en 2008

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

artículo científico publicado en 2010

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2015

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

artículo científico publicado en 2010

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

artículo científico publicado en 2007

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

artículo científico publicado en 2015

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

artículo científico publicado en 2003

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

artículo científico publicado en 2009

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

artículo científico publicado en 2009

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

artículo científico publicado en 2008

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

artículo científico publicado en 2002

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

artículo científico publicado en 2012

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

artículo científico publicado en 2006

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

artículo científico publicado en 2003

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

artículo científico publicado en 2014

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

artículo científico publicado en 2012

Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives

artículo científico publicado en 2002

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

artículo científico publicado en 2007

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

artículo científico publicado en 2002

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase

artículo científico publicado en 2011

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

artículo científico publicado en 2006

Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia

artículo científico publicado en 2008

Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system

artículo científico publicado en 2012

Prediction model for mortality after intracranial hemorrhage in patients with leukemia

artículo científico publicado en 2011

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2010

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2006

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

artículo científico publicado en 2012

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

artículo científico publicado en 2013

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

artículo científico publicado en 2016

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2007

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

artículo científico publicado en 2008

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin

artículo científico publicado en 2011

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

artículo científico publicado en 2003

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

artículo científico publicado en 2003

Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia

artículo científico publicado en 2008

Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes

artículo científico publicado en 2013

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

artículo científico publicado en 2003

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

artículo científico publicado en 2008

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

artículo científico publicado en 2010

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

artículo científico publicado en 2003

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

artículo científico publicado en 2004

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

artículo científico publicado en 2006

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

artículo científico publicado en 2003

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

artículo científico publicado en 2003

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

artículo científico publicado en 2013

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

artículo científico publicado en 2008

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

artículo científico publicado en 2003

Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells

artículo científico publicado en 2003

Rituximab in relapsed or refractory hairy cell leukemia

artículo científico publicado en 2003

STAT-3 Activates NF-κB in Chronic Lymphocytic Leukemia Cells ⬇️

artículo científico publicado el 1 de marzo de 2011

STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis

artículo científico publicado en 2014

Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia

artículo científico publicado en 2017

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD

artículo científico publicado en 2013

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells

artículo científico publicado en 2013

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

artículo científico publicado en 2005

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

artículo científico publicado en 2009

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications

artículo científico publicado en 2011

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

artículo científico publicado en 2002

Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia

artículo científico publicado en 2003

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

artículo científico publicado en 2006

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

artículo científico publicado en 2009

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

artículo científico publicado en 2004

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

artículo científico publicado en 2005

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

artículo científico publicado en 2009

Sweet's syndrome in chronic lymphocytic leukemia associated with neutropenic fever and granulocyte colony stimulation factor.

artículo científico publicado en 2006

Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia

artículo científico publicado en 2004

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

artículo científico publicado en 2013

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2011

The biology and therapy of adult acute lymphoblastic leukemia ⬇️

artículo científico publicado el 1 de octubre de 2003

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

artículo científico publicado en 2008

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

artículo científico publicado en 2009

The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog

artículo científico publicado en 2005

The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

scientific article published on December 2016

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

artículo científico publicado en 2004

The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells

artículo científico publicado en 2010

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

scientific article published on 03 September 2009

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

artículo científico publicado en 2008

Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens

artículo científico publicado en 2009

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

artículo científico publicado en 2008

Treatment algorithms in CLL.

artículo científico publicado en 2005

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

artículo científico publicado en 2003

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

artículo científico publicado en 2003

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival

artículo científico publicado en 2008

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

artículo científico publicado en 2002

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome

artículo científico publicado en 2006

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

artículo científico publicado en 2012

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

artículo científico publicado en 2005

Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy

artículo científico publicado en 2012

WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).

artículo científico publicado en 2005

WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells

artículo científico publicado en 2007

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda